RespireRx Pharmaceuticals Inc

RespireRx Pharmaceuticals — Investor Presentation (December 2018)

10 slides from RespireRx Pharmaceuticals's investor presentation, Dec 10, 2018

  1. Slide 1: The Funding Challenges Associated with Cannabis-Derived Pharmaceuticals

    RN RespireRx Pharmaceuticals Inc. The Funding Challenges Associated with Cannabis-Derived Pharmaceuticals Presented December 12, 2018 deff Margolis SVP CFO ete RespireRx Pharmaceuticals

  2. Slide 2: Forward-Looking Statements

    oa) RespireRx eo re Inc ies Exchange Act of 1934 (the “Exchange Act”) and the Company intends the Company's future plans, targets, estimates, assumptions, financial Juding, but not limited to, preclinical and clinical research design, This presentation contains certain forward-looking statements wit

  3. Slide 3: Need to Distinguish Cannabinoids from Cannabis

    Need to Distinguish Cannabinoids from Cannabis We think of Cannabinoids as following a federally regulated drug development pathway * — Often synthetic - dronabinol is AS-THE ¢ Ean be plant derived - Epidiolex® ¢ Ean be plant derived and modified We think of Cannabis as being associated with the pla

  4. Slide 4: Investor (and Regulator/Lawmaker) Education Needed

    Investor (and Regulator/Lawmaker) Education Needed In the Cannabinoid market, rationalization will make education easier ¢ — Drug development and commercialization, which are federally regulated with products that are federally legal, represents an infrastructure with which drug developers and inves

  5. Slide 5: Investor (and Regulator/Lawmaker) Education Needed

    Investor (and Regulator/Lawmaker) Education Needed In the United States, the Cannabis universe is more difficult to understand ¢ State laws vary from state to state, enforcement varies and almost nothing is federally legal ¢ — Cole Memorandum added some rationalization and predictability ¢ — Rescind

  6. Slide 6: Commercial Banking Firms

    Commercial Banking Firms In the United States, commercial banks find it difficult if not impossible to provide traditional banking services to Cannabis companies. We believe that: this is due to the federal illegality * the anti-money laundering laws, rules and regulations play a role ¢ the rescissi

  7. Slide 7: Securities Clearing Firms

    Securities Clearing Firms ¢ Atleast some securities clearing firms have refused to hold and clear securities transactions, particularly private securities transactions in Cannabis companies. + This situation makes trading in the stock of such companies more difficult and therefore capital formation

  8. Slide 8: Canada and the U.S. and Israel

    Canada and the U.S. and Israel Canada ¢ — Recreational marijuana now legal in Canada + At present, Canadian financial markets, particularly in Toronto, are receptive + According to Forbes (Sept 26, 2018), there are about 120 Cannabis companies listed on Canadian exchanges of which approximately 100

  9. Slide 9: Canada and the U.S. and Israel

    Canada and the U.S. and Israel United States + Difficult financial market regulatory market, especially after the rescission of the Cole Memorandum. + More difficult for Cannabis because Cannabis is still federally illegal. + Less difficult for Cannabinoid-derived pharmaceuticals due to FDA and fede

  10. Slide 10: The Funding Challenges Associated with Cannabis-Derived Pharmaceuticals

    RN RespireRx Pharmaceuticals Inc. The Funding Challenges Associated with Cannabis-Derived Pharmaceuticals Presented December 12, 2018 deff Margolis SVP CFO ete RespireRx Pharmaceuticals

RespireRx Pharmaceuticals — Investor Presentation (December 2018) on 6ix